Home › Kanser sa Bato (Renal Cell Carcinoma) › Nebraska › Omaha
Pag-aaral pangklinika para sa Kanser sa Bato (Renal Cell Carcinoma) sa Omaha, NE
Isang pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) ang naghahanap ng mga kalahok sa isang site sa loob o malapit sa Omaha. Buksan ito upang makita kung sino ang makakasali at kung paano makipag-ugnayan sa koponan ng pag-aaral.
Opisyal na teksto ng pag-aaral (English)
A Phase 1 Study of AB521 Monotherapy and Combination Therapies in Renal Cell Carcinoma and Other Solid Tumors
Nagre-recruitPhase 1
- Research Site, Omaha
Open-Label Phase 1/2 Study of NEO-811 in Subjects With Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- NEO-811 Omaha Site, Omaha
A Phase 1 Study of the Safety and Tolerability of CTX-10726
Nagre-recruitPhase 1
- Nebraska Cancer Specialists, Omaha
Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
Nagre-recruitObservasyonal na pag-aaralMalugod na tinatanggap ang malusog na boluntaryo
- Alegent Health Immanuel Medical Center, Omaha
- Alegent Health Bergan Mercy Medical Center, Omaha
- Alegent Health Lakeside Hospital, Omaha
Study of Zanzalintinib in Combination With Immuno-Oncology or Other Agents in Participants With Solid Tumors
Nagre-recruitPhase 1
- Exelixis Clinical Site #2, Omaha
Testing the Effectiveness of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) With One Anti-cancer Targeted Drug (Cabozantinib) for Rare Genitourinary Tumors
Nagre-recruitPhase 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi ang layo
A Study of Theranostic Pair PD-32766D/T in Participants With Carbonic Anhydrase IX Positive Clear Cell Renal Cell Carcinoma
Nagre-recruitPhase 1
- Research site, Omaha
Testing the Addition of Stereotactic Radiation Therapy With Immune Therapy for the Treatment of Patients With Unresectable or Metastatic Renal Cell Cancer, SAMURAI Trial
Nagre-recruitPhase 2
- Nebraska Medicine-Village Pointe, Omaha
- University of Nebraska Medical Center, Omaha
- Nebraska Medicine-Bellevue, Bellevue · 9 mi ang layo
A Study to Evaluate INCA036873 in Participants With Advanced Solid Tumors and Hematological Malignancies
Nagre-recruitPhase 1
- The University of Nebraska Medical Center, Omaha
A Clinical Study of Belzutifan and Zanzalintinib in People With Recurrent Kidney Cancer Following Adjuvant Therapy (MK-6482-033)
Nagre-recruitPhase 3
- Oncology Hematology West P.C. dba Nebraska Cancer Specialists ( Site 0131), Omaha
Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
Nagre-recruitPhase 1/2
- Nebraska Cancer Specialists, Omaha
Comparing the Outcome of Immunotherapy-Based Drug Combination Therapy With or Without Surgery to Remove the Kidney in Metastatic Kidney Cancer, the PROBE Trial
Nagre-recruitPhase 3
- Nebraska Cancer Specialists/Oncology Hematology West PC - MECC, Omaha
- Nebraska Methodist Hospital, Omaha
- Oncology Associates PC, Omaha
Pag-aaral para sa Kanser sa Bato (Renal Cell Carcinoma) sa ibang lungsod
- Houston, TX35 pag-aaral
- New York City, NY27 pag-aaral
- Nashville, TN23 pag-aaral
- Dallas, TX23 pag-aaral
- St. Louis, MO23 pag-aaral
- Los Angeles, CA20 pag-aaral
- Boston, MA16 pag-aaral
- Baldwin Park, CA16 pag-aaral
- Philadelphia, PA15 pag-aaral
- Pittsburgh, PA15 pag-aaral
- Queens, NY15 pag-aaral
- Cleveland, OH14 pag-aaral
Iba pang pag-aaral sa Omaha
- Kanser sa Prostate27 pag-aaral
- Non-Small Cell Lung Cancer24 pag-aaral
- Kanser sa Suso22 pag-aaral
- Kanser (lahat ng uri)18 pag-aaral
- Colorectal Cancer18 pag-aaral
- Multiple Myeloma16 pag-aaral
- Kanser sa Ovary14 pag-aaral
- Non-Hodgkin Lymphoma14 pag-aaral
- Kanser sa Pancreas14 pag-aaral
- Metastatic Cancer13 pag-aaral
- Squamous Cell Carcinoma ng Ulo at Leeg13 pag-aaral
- Pagkabigo ng Puso13 pag-aaral
Mula sa ClinicalTrials.gov, na-kuha noong Okt 6, 2026. Ang bawat pag-aaral ay may sariling pamantayan sa eligibility; ang koponan ng pag-aaral ang magdedesisyon kung sino ang makakasali.